Aditya Bagrodia

Maybe that's warm irrigation for a Sisto versus room temperature. Maybe it's headphones. Maybe it's, you know, I don't know, picking their favorite playlist on Spotify and you go with it. And then at that time of the intervention, so to speak, the system, the biopsy, the whatever, music in the OR, you're saying, okay, now we're going to intervene. Is that still okay? You're excited about it.

Maybe that's warm irrigation for a Sisto versus room temperature. Maybe it's headphones. Maybe it's, you know, I don't know, picking their favorite playlist on Spotify and you go with it. And then at that time of the intervention, so to speak, the system, the biopsy, the whatever, music in the OR, you're saying, okay, now we're going to intervene. Is that still okay? You're excited about it.

Maybe that's warm irrigation for a Sisto versus room temperature. Maybe it's headphones. Maybe it's, you know, I don't know, picking their favorite playlist on Spotify and you go with it. And then at that time of the intervention, so to speak, the system, the biopsy, the whatever, music in the OR, you're saying, okay, now we're going to intervene. Is that still okay? You're excited about it.

You collect the outcome and you're cruising. Does this sound about right?

You collect the outcome and you're cruising. Does this sound about right?

You collect the outcome and you're cruising. Does this sound about right?

No, I mean, these are tremendous pearls before. I mean, the clinical integration of trials, the two-stage consent. What are some of the other things that you feel have been particularly effective in your illustrious clinical trials enrollment career?

No, I mean, these are tremendous pearls before. I mean, the clinical integration of trials, the two-stage consent. What are some of the other things that you feel have been particularly effective in your illustrious clinical trials enrollment career?

No, I mean, these are tremendous pearls before. I mean, the clinical integration of trials, the two-stage consent. What are some of the other things that you feel have been particularly effective in your illustrious clinical trials enrollment career?

Makes sense, right? I mean, you see perfect examples of that. You know, one recent one that comes into mind is the recent BRIDGE study comparing BCG versus gem dose C for non-most invasive high-risk bladder cancer. The study PI did a small pilot at their home institution. It went well. And then through the cooperative groups, we're able to get something substantial moving.

Makes sense, right? I mean, you see perfect examples of that. You know, one recent one that comes into mind is the recent BRIDGE study comparing BCG versus gem dose C for non-most invasive high-risk bladder cancer. The study PI did a small pilot at their home institution. It went well. And then through the cooperative groups, we're able to get something substantial moving.

Makes sense, right? I mean, you see perfect examples of that. You know, one recent one that comes into mind is the recent BRIDGE study comparing BCG versus gem dose C for non-most invasive high-risk bladder cancer. The study PI did a small pilot at their home institution. It went well. And then through the cooperative groups, we're able to get something substantial moving.

I don't see it as a sellout to test the waters and see how it's going to go, you know, because we've seen amazing, ambitious trials, a dime a dozen, unfortunately, answering really critical questions that just never got off the ground. Fantastic before.

I don't see it as a sellout to test the waters and see how it's going to go, you know, because we've seen amazing, ambitious trials, a dime a dozen, unfortunately, answering really critical questions that just never got off the ground. Fantastic before.

I don't see it as a sellout to test the waters and see how it's going to go, you know, because we've seen amazing, ambitious trials, a dime a dozen, unfortunately, answering really critical questions that just never got off the ground. Fantastic before.

So, you know, as we approach an hour here, you know, I wanted to maybe just have you run through, you know, lessons learned, things that work, things that didn't work. You've touched on some of the pearls and some of the pitfalls, but any that we didn't cover?

So, you know, as we approach an hour here, you know, I wanted to maybe just have you run through, you know, lessons learned, things that work, things that didn't work. You've touched on some of the pearls and some of the pitfalls, but any that we didn't cover?

So, you know, as we approach an hour here, you know, I wanted to maybe just have you run through, you know, lessons learned, things that work, things that didn't work. You've touched on some of the pearls and some of the pitfalls, but any that we didn't cover?

I love it before. And I can think back to the early days when I was just starting and kind of knew that germ cell testis was going to be my primary area of interest. And the SEMS trial was just kind of getting going. And I reached out to SIA. We opened it there. And I was literally so thrilled to put four patients on. And that did give me some validity within my own kind of institution, region.

I love it before. And I can think back to the early days when I was just starting and kind of knew that germ cell testis was going to be my primary area of interest. And the SEMS trial was just kind of getting going. And I reached out to SIA. We opened it there. And I was literally so thrilled to put four patients on. And that did give me some validity within my own kind of institution, region.